Los Angeles Capital Management LLC Has $32.39 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Los Angeles Capital Management LLC grew its position in IQVIA Holdings Inc. (NYSE:IQVFree Report) by 8.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 128,089 shares of the medical research company’s stock after purchasing an additional 9,473 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.07% of IQVIA worth $32,392,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the business. AdvisorNet Financial Inc boosted its stake in IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares in the last quarter. BKM Wealth Management LLC purchased a new position in shares of IQVIA in the 4th quarter worth about $32,000. Activest Wealth Management bought a new position in IQVIA during the fourth quarter valued at $35,000. Security National Bank bought a new stake in shares of IQVIA in the fourth quarter valued at approximately $41,000. Finally, CVA Family Office LLC purchased a new stake in shares of IQVIA during the 4th quarter valued at approximately $43,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IQV. The Goldman Sachs Group began coverage on shares of IQVIA in a research note on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective for the company. Truist Financial decreased their price objective on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research note on Friday, May 3rd. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Evercore ISI decreased their price target on IQVIA from $275.00 to $250.00 and set an “outperform” rating on the stock in a research report on Friday, May 3rd. Finally, Robert W. Baird cut their price objective on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a research report on Friday, May 3rd. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $258.40.

View Our Latest Stock Analysis on IQVIA

IQVIA Stock Down 0.2 %

IQVIA stock traded down $0.49 during mid-day trading on Wednesday, hitting $212.83. The company had a trading volume of 1,099,382 shares, compared to its average volume of 1,221,324. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02. The stock’s 50 day moving average price is $226.94 and its two-hundred day moving average price is $230.40. The company has a market capitalization of $38.78 billion, a PE ratio of 29.09, a price-to-earnings-growth ratio of 1.94 and a beta of 1.53.

IQVIA (NYSE:IQVGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.19 by $0.11. The company had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

IQVIA Company Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Stories

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.